For this project he identifies appropriate participants from the HMDS Outreach monitoring service for patients with early-stage haematological malignancies not requiring immediate treatment. He supervises flow cytometry analyses and ensures appropriate material is stored/transferred to biobank for the relevant work packages.

Professor Andy Rawstron qualified from Edinburgh University with a BSc in Immunology in 1992. He became a Clinical Scientist at the Haematological Malignancy Diagnostic Service in Leeds and was awarded a Doctor of Philosophy in 2002.

Prof Rawstron’s work into the understanding of CLL, both in terms of defining the nature of Monoclonal B-Lymphocytosis and in developing and standardizing the assessment of minimal residual disease (MRD) in CLL, has been internationally recognized. His work in coordinating a standard approach to MRD analysis in CLL has encouraged close collaboration between many of the laboratories on the cutting edge of CLL research.

Professor Rawstron has a «routine» service commitment in the development, selection and interpretation of relevant tests for the diagnosis, treatment and monitoring of haematological malignancy.

Within this role he has developed a National award-winning service for monitoring people with MGUS (monoclonal gammopathy of unknown significance) or early stage CLL.